Renal Cell Carcinoma

In a presentation at the 2023 International Kidney Cancer Symposium, Maxine Sun, PhD, MPH, discussed the relationship between clonal hematopoiesis in patients with kidney cancer and their risk for cardiac events.

The RCC Cancer Immunity Cycle may inform the treatment and development of novel therapies in renal cell carcinoma moving forward.

An expert discussed how the use of circulating tumor DNA in patients with RCC may help guide whether treatment should be intensified or deescalated.

Alan Tan, MD, discusses areas of interest in the research and development of circulating tumor DNA in renal cell carcinoma.

Results unveiled at the 2023 International Kidney Cancer Symposium revealed that patients with advanced clear cell renal cell carcinoma in the 200-mg dose group achieved an overall response rate of 23.1% based on blinded independent central review.

In a presentation at the 2023 International Kidney Cancer Symposium, Jaleh Fallah, MD, discussed the regulatory agency’s evaluation of data from the phase 2 LITESPARK-004 trial, which led to the approval of belzutifan.

Patients with advanced clear cell renal cell carcinoma treated with zanzalintinib had experienced promising antitumor activity with manageable toxicity regardless of prior treatment with cabozantinib.

An expert discussed how recent studies in patients with translocation RCC, a rare type of RCC, have demonstrated that the disease responds well to immune checkpoint inhibitors, but more focus is needed on novel targets to treat it.

The combination of SRK-181 and pembrolizumab demonstrated improvements in objective response rate among patients with clear cell renal cell carcinoma in a phase 1 proof-of-concept study.

Bradley McGregor, MD, discusses the rationale behind the multi-institutional, prospective, single-arm phase 2 trial of cabozantinib, nivolumab, and ipilimumab for the treatment of patients with renal cell carcinoma with variant histologies.

In separate, live virtual events, Robert J. Motzer, MD; and Moshe Ornstein, MD, MA, discussed the case of a patient with metastatic clear cell renal cell carcinoma (RCC) and options for therapy.

During a Targeted Oncology™ Case-Based Roundtable™ event, Benjamin Garmezy, MD, and participants discussed their takeaways from the phase 3 trials of immunotherapy and tyrosine kinase inhibitors in frontline renal cell carcinoma. This is the second article based on this event.

In the KEYNOTE-564 trial, patients with renal cell carcinoma who had a nephrectomy achieved improved overall survival rates vs placebo when treated with adjuvant pembrolizumab.

Hans Hammers, MD, PhD, discusses the case of a 59-year-old African American woman with clear cell renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Arnab Basu, MD, MPH, asked participants about what sequence of therapies they would use in the first, second, and third lines for a patient with metastatic clear cell renal cell carcinoma. This is the first of 2 articles based on this event.

In the phase 3 CLEAR study, lenvatinib combined with pembrolizumab continued to elicit deep and durable tumor response among patients with advanced clear cell renal cell carcinoma.

Belzutifan led to improved progression-free survival and objective response rate compared to everolimus for patients with advanced clear cell renal cell carcinoma, according to study findings.

“Belzutifan plus cabozantinib continue to show durable anti-tumor activity in patients with clear cell RCC who are treatment naïve or previously treated,” said Toni K. Choueiri, MD.

The phase 3 CheckMate -67T trial found that a subcutaneous formulation of nivolumab met its co-primary pharmacokinetic end points compared with the intravenous formulation in clear cell renal cell carcinoma.

The tool shows promise to predict a patient’s response to dovitinib to better inform treatment options for patients with renal cell carcinoma and other solid tumors.

During a Targeted Oncology™ Case-Based Roundtable™ event, Daniel George, MD, discussed the CheckMate 9ER trial in terms of bone, liver, and lung metastases and other subgroups in patients with advanced clear cell renal cell carcinoma.

In the first article of a 2-part series, Benjamin Garmezy, MD, discusses risk stratification and combination options in the metastatic clear cell renal cell carcinoma setting.

Results from the EVEREST study do not support the adjuvant use of everolimus for patients with renal cell carcinoma following surgery.

Yann-Alexandre Vano, MD, discusses some of the exciting data being seen in the renal cell carcinoma space.

Robert J. Motzer, MD, concludes the program with insights on promising treatment options for patients with non–clear cell renal cell carcinoma.

Combination therapies for patients with advanced renal cell carcinoma provides clinicians with new treatment avenues for their patients. To assess which path to go down, Tian Zhang, MD, MHS, and Randy F. Sweis, MD, led virtual discussions on evaluating patients’ risk criteria to determine their proper treatment.

In an interview, Chung-Han Lee, MD, PhD, discussed the challenges, studies, and outcomes previously observed when studying adjuvant treatments for patients with renal cell carcinoma.

Chung-Han Lee, MD, PhD, discusses the types of research that are needed to push forward the development of adjuvant treatments for patients with renal cell carcinoma.

Samer A. Srour, MB, ChB, MS, discusses the design of ALLO-316, an agent investigated in the phase 2 TRAVERSE trial for patients with renal cell carcinoma.

A medical oncologist reviews recent data updates from the 2023 ASCO Annual Meeting for non–clear cell renal cell carcinoma.